| Time | Pre-Congress Workshop 1 Kidney transplant immunopathology |
Pre-Congress Workshop 2 Organ donation & procurement |
Pre-Congress Workshop 3 Workup of potential transplant recipients |
| 0815-0830 | Course overview | Course overview | Course overview |
| 0830-0900 | 0830 – 0915 The immune response to transplantation |
Active donor detection in Spain. Is there a wrong or a right way to do it? | CKD burden in Asia |
| 0900-0930 | 0915 – 0930 BREAK |
Ancillary testing in brain death | Economics of transplantation in Asia |
| 0930-1000 | 0930 – 1015 Immune cells involved in transplantation rejection |
Updates on donor maintenance to deliver quality organs for transplantation | Optimising potential recipients for kidney transplantation |
| 1000-1030 | COFFEE BREAK | ||
| 1030-1100 | 1030 – 1115 Tissue typing and detection of pre-formed antibodies |
Understanding refusals: what makes family consent? | Evaluation of kidney transplant recipients – an overview |
| 1100-1130 | 1115 – 1145 Induction therapy |
Challenges in family donor conversation | Surgical aspects of kidney transplant recipients |
| 1130-1200 | 1145 – 1200 BREAK |
Consensus guideline on immunological evaluation of transplant recipients | |
| 1200-1230 | Desensitisation – HLA antibodies, ABOi transplantation | Bringing teams together, sharing experience | Managing the original kidney disease |
| 1230-1300 | Immunosuppressive drugs | Normothermic machine perfusion for liver allograft: current evidence | Pre-transplant cardiac evaluation |
| 1300 -1400 | LUNCH | ||
| 1400-1430 | Renal allograft histopathology: Banff Classification | HCV and HIV positive donors | Evaluation of liver transplant recipients |
| 1430-1500 | T cell mediated rejection | Biological markers in organ donation and transplantation: an update | Surgical aspects of liver transplant recipients |
| 1500-1530 | 1500 – 1515 BREAK |
The power of social media and how it can affect organ donation | Pediatric renal recipient work-up |
| 1530-1600 | 1515 – 1545 Antibody mediated rejection: diagnosis and management |
Organ donation and COVID 19: Clinical issues | What does the HLA crossmatch mean? |
| Organ donation and COVID 19: World registries | |||
| 1600-1630 | 1545 – 1630 Strategies for achieving tolerance |
i-DTI and telemedicine | Frailty-assessment and prognosis |
| Artificial intelligence and robotics in organ donation | |||
| 1700-1830 | OPENING CEREMONY | ||
| Time | PLENARIES | |||
| 0830-0900 | Plenary 1: Management of transplantation in the digital era | |||
| 0900-0930 | Plenary 2: Updates on Tregs and tolerance | |||
| 0930-1000 | Plenary 3: The challenges of prolonging kidney allograft survival | |||
| 1000-1030 | COFFEE BREAK | |||
| 1030-1230 | STATE OF THE ART SYMPOSIUM (1) | |||
| Kidney transplant | Liver transplant | Heart & Lung | Donation & ethics | |
| 1030-1050 | Deceased donor kidney quality and allograft outcome | Epidemiology of non-alcoholic fatty liver and non-alcoholic steatohepatitis: implications for liver transplantation | Setting up a pediatric heart transplant and MCS (mechanical circulatory support) programme | The Declaration of Istanbul on Organ Trafficking and Transplant Tourism 2018 |
| 1050-1110 | Long-term living donor outcome: cause for concern? | Role of bridging therapies in acute and acute-on-chronic liver failures | mTOR Inhibitors in heart transplantation | Importance of post donation care: a comparison of practices around the world |
| 1110-1130 | Causes of death with function – what can we do to prevent it? | Emerging indications for liver transplantation | Pulmonary hypertension and lung transplantation | Malaysia: curbing illegal overseas transplantation. Should we deny recipients of free immunosuppressants? |
| 1130-1150 | Managing a second transplant | Living donor liver transplantation for acute on chronic liver failure | Bridging to lung transplantation: who, when and with what? | DCD – Euthanasia, withdrawal of therapy, reintubation…where do we draw the line? |
| 1150-1210 | Trials in kidney transplantation | Selection criteria for transplantation in HCC | Future technology in ventricular assist devices | Opting in vs opting out: which works better? |
| 1210-1230 | ||||
| 1230-1400 | INDUSTRY SPONSORED LUNCH SYMPOSIUM | |||
| 1400-1540 | ABSTRACT PRESENTATIONS (selected oral presentations) |
|||
| 1540-1610 | COFFEE BREAK | |||
| 1610-1640 | Plenary 4: Chimerism, transplant tolerance and beyond Megan Sykes | |||
| 1640-1800 | DEBATES and STATE OF THE ART SYMPOSIUM (2) | |||
| Kidney - debates | Liver - debates | Heart & Lung | Transplantation and COVID 19 | |
| 1640-1720 | Living donors should be incentivised | Active drinkers should be transplanted | Artificial intelligence in LVAD implantation (20 mins) |
COVID 19: Virology and pathogenesis (15 mins) |
| Less invasive VAD Implantation (20 mins) |
SARS Coronavirus 2: Update on clinical trials (15 mins) |
|||
| 1720-1800 | Robotic renal transplantation vs Open renal transplantation – which is a better technique? | Liver transplantation for liver metastasis | Late complications following lung transplantation (20 mins) |
Clinical presentation, complications, and outcomes in solid organ transplant recipients (25 mins) |
| Living related lung transplant – Japanese model (20 mins) |
Management of the transplant programme in the time of COVID-19 (25 mins) |
|||
| Time | PLENARIES AND REGISTRIES | |||
| 0800-0830 | Plenary 5: Liver transplantation in metastatic liver disease | |||
| 0830-0900 | Plenary 6: 50 donors p.m.p. is not a dream anymore: how did Spain do it? | |||
| 0900-1000 | Asian transplantation registries for collaboration and harmony 0900-0915: What can we learn from registries? 0915-0930: Setting up an Asian registry for COVID-19 0930-0945: Setting up an Asian registry for transplantation tourism 0945-1000: Improving harmony among registries |
|||
| 1000-1030 | COFFEE BREAK | |||
| 1030-1230 | STATE OF THE ART SYMPOSIUM (3) | |||
| Kidney transplant | Liver transplant | Heart & Lung | Surgical aspects of kidney transplantation | |
| 1030-1050 | T cell mediated rejection | Current trends of immunosuppression in liver transplantation | Organ donation innovative strategy in South East Asia (Odissea). what have we learnt? | The complex living donor |
| 1050-1110 | Highly sensitised recipient: desensitisation strategies-: practical approaches | Acute liver failure and transplantation – indicators for poor outcome | Deceased donation. should we allow donor family to meet recipients? | The complex recipient |
| 1110-1130 | Management of ABMR: Current updates | ABO incompatible liver transplantation | Overcoming cultural barriers. is this the key to gaining consent? | Role of interventional radiologist in kidney transplantation |
| 1130-1150 | Paired kidney exchange: success and challenges and lesson learnt | Hepatitis B reactivation post liver transplantation | Increasing demand on master education for donation & transplantation. | Coping with donor complications |
| 1150-1210 | ABO incompatible renal transplantation | Role of Interventional radiology post liver transplant | Burnout amongst donor coordinators: is it real? | When should I not proceed with kidney transplantation from a surgical perspective? |
| 1210-1230 | ||||
| 1230-1400 | INDUSTRY SPONSORED LUNCH SYMPOSIUM | |||
| 1400-1600 | STATE OF THE ART SYMPOSIUM (4) | |||
| Transplant immunology | Surgical aspects of liver transplantation | Transplant infectious disease | Biomarkers in transplantation | |
| 1400-1420 | What is immunological risk? | Advances in surgical techniques in living donor liver transplantation | Asymptomatic bacteriuria post kidney transplantation: what to do | Biomarkers in acute rejection |
| 1420–1440 | High resolution HLA typing in solid organ transplantation: is it necessary? | Laparoscopic living donor hepatectomy: safety and efficacy | Unusual infections from deceased donors | Biomarkers in chronic allograft dysfunction |
| 1440-1500 | HLA mismatching and kidney transplant outcomes: what matters? | Long term liver transplant outcomes | Difficult fungal infections: diagnostic approaches and management | Role of biomarkers in personalised Immunosuppression: are we there yet? |
| 1500–1520 | Denovo DSA: Risk factors and clinical consequences | Organ preservation | Latent TB: detection and management | Gut microbiome in solid organ transplantation |
| 1520–1540 | Clinical relevance of non-HLA antibodies | Pediatric liver transplantation | Respiratory viral infections in transplant recipients | Cell-free DNA and active rejection in kidney allografts |
| 1540-1550 | ||||
| 1550-1620 | COFFEE BREAK | |||
| 1620–1800 | STATE OF THE ART SYMPOSIUM (5) | |||
| Kidney | Women in transplantation | Transplant immunology | Post-transplant complications | |
| 1620-1640 | Belatacept in kidney transplant: past and future perspectives | Equity in donors and recipients in places with disparities | Eplet matching in kidney transplantation | Transplant-associated thrombotic microangiopathy - more than just clot and bleed |
| 1640-1700 | Optimising mycophenolic acid exposure in kidney transplant recipients: time for target concentration intervention | Equity in leadership | Role of DSA monitoring post kidney transplantation | Post- transplant lymphoproliferative disorders |
| 1700-1720 | Can mTORi be combined with CNI in renal transplantation? Experimental and clinical evidence | Fertility and pregnancy post solid organ transplantation | The influence of immunosuppressive agents on the risk of denovo DSA in solid organ transplant recipients | Risk of cancer after solid organ transplant in childhood |
| 1720-1740 | Evolution of Banff Classification: 20 years ahead | Sensitisation during pregnancy: what is the impact? | Targeting complement as rejection therapy | Obesity and metabolic syndrome post transplantation: prevention and management |
| 1740-1800 |
MicroRNA profiles predictive of organ allograft status
|
How women can bring change to organ transplantation - the Mongolian experience | The role for inhibition of the CD40-CD154 pathway in co-stimulation blockade | Medication adherence |
| Time | PLENARIES | ||||||
| 0800-0830 | Plenary 7: The role of B cells in transplantation | ||||||
| 0830-0900 | Plenary 8: Experimental xenotransplantation | ||||||
| 0900-1000 | STATE OF THE ART SYMPOSIUM (6) and TRANSPLANTATION IN ASIA | ||||||
| Innovation in transplantation | Post-transplant complications | Asian experts in Transplantation | |||||
| 0900-0920 | Artificial kidneys | Cardiovascular disease & dyslipldaemia in transplantation | Translational research in transplantation | ||||
| 0920-0940 | Clinical transplantation: how do we measure performance? | Current strategies in post-transplant diabetes mellitus | CD47 in xenotransplantation | ||||
| 0940-1000 | Future of research in transplantation | Bone disease post transplantation: spectrum, impact, prevention and management | Role of macrophages in transplant oncology and immunology | ||||
| 1000-1030 | COFFEE BREAK | ||||||
| 1030-1200 | ABSTRACT PRESENTATIONS (selected oral presentations) |
How to improve self-sufficiency in Asia? The experience in various countries | |||||
| 1200- 1230 | Panel discussion: How to achieve self-sufficiency in Asia? (30 mins) | ||||||
| 1230-1400 | INDUSTRY SPONSORED LUNCH SYMPOSIUM | ||||||
| STATE OF THE ART SYMPOSIUM (7) | |||||||
| Transplantation in Asia – challenges & way forward | Transplant infectious diseases | ||||||
| 1400-1420 | Role of Vitallink in advancing transplantation in Asia | CMV: Consensus on monitoring, prevention, and therapeutic updates |
ASTREG Workshop for registry (for Small group meeting |
The ODiSSeA project (Malaysia, |
|||
| 1420-1440 | Longest on waiting list vs fittest and shortest waiting time gets the kidney | Current perspectives of BKV in transplant recipients | |||||
| 1440-1500 | The Spanish model: can it be implemented in Asia? | Hepatitis C: When is the optimal time to treat? | |||||
| 1500-1510 | |||||||
| 1515-1600 | CLOSING CEREMONY & AWARDS CEREMONY | ||||||
(Updates as 1 December 2020)